(Reuters) – Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases, the companies said on Tuesday.
(Reporting by Pratik Jain in Bengaluru; Editing by Shounak Dasgupta)
